Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of…
<!-- Name:DistributionId Value:8738569 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Atacicept
Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical…
Atacicept met primary endpoint at 24 weeks, and also achieved statistical significance in the 150 mg dose group with a 33% mean reduction in proteinuria from baseline, with available data…
Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of…
BRISBANE, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative…
Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral…
Atacicept is the first known investigational therapy to decrease both circulatory Gd-IgA1 and anti-Gd-IgA1 autoantibodies which correlate with increased risk of IgA nephropathy disease…
Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal…
BRISBANE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative…
Vera Therapeutics Presents Phase 2a Data Showing Atacicept Reduces Serum Gd-IgA1 in…
Phase 2a JANUS clinical trial showed atacicept administered subcutaneously once weekly demonstrated a durable and substantial reduction in serum galactose-deficient IgA1 (Gd-IgA1) in a…